Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

    -- our ability to borrow additional amounts under the loan from Bay City
       Capital, which is subject to the discretion of Bay City Capital;
    -- our ability to obtain necessary financing in the near term, including
       amounts necessary to repay the loan from Bay City Capital by the
       September 14, 2009 maturity date (or earlier if certain repayment
       acceleration provisions are triggered);
    -- our ability to control our operating expenses;
    -- our ability to comply with covenants included in the loan from Bay
       City Capital;
    -- our ability to maintain the listing of our common stock on NASDAQ;
    -- our failure to timely recruit and enroll patients for the FDG-PET
       clinical trial, as well as any future clinical trial;
     -- our failure to obtain sufficient data from enrolled patients that can
       be used to evaluate VIA- 2291, thereby impairing the validity or
       statistical significance of our clinical trials;
    -- our ability to successfully complete our clinical trials of VIA-2291
       on expected timetables and the outcomes of such clinical trials;
    -- complexities in designing and implementing cardiovascular clinical
       trials using histological examinations, measurement of biomarkers,
       medical imaging and atherosclerotic plaque bioassays;

'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Market Snapshot: Transcatheter Heart Valve 2007 to ... France , Italy , UK, Spain ... 2007 to 2020 - Europe ( Germany ... Spain )" provides quantitative analysis of the transcatheter heart valves market ... revenue and volume over the 2007–2020 period and key company share data by ...
(Date:9/23/2014)... , Sept. 23, 2014  SI-BONE, Inc., a ... iFuse Implant System, ® a minimally invasive surgical ... joint, today announced that the U.S. Patent and Trademark ... systems and methods for the fixation and fusion of ... fenestrated implant with a tapered distal end that may be placed from ...
(Date:9/23/2014)... 23, 2014  Global Discovery Biosciences, a laboratory dedicated ... the biggest healthcare challenges, announces their collaboration with IPMD, ... test for the early detection of lung cancer. ... death. Typically, the symptoms and subsequent diagnosis of lung ... the chance of a cure has already passed. Early ...
Breaking Medicine Technology:Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3Global Discovery Biosciences Announces Collaboration with IPMD, Inc. to Develop Innovative Aptamer-Based Blood Test for the Early Detection of Lung Cancer 2
... Feb. 7, 2011 ConvaTec, a world-leading developer and ... care, today announced the appointment of several executives to ... Pionati has been appointed President, Intercontinental in a newly ... and Canada. These markets continue to be a strategic ...
... Corp. (Nasdaq: BSTC ; the "Company" or ... products, today announced that its Board of Directors has ... 14, 2002 and previously amended June 19, 2003 (the ... for determining "Acquiring Person" status under the Rights Agreement ...
Cached Medicine Technology:ConvaTec Announces New Appointments to Leadership Team 2
(Date:9/23/2014)... The inaugural single day event in Japan will ... Gardens in Tokyo. Clinical data scientists will meet and discuss ... second single day event in China will be ... clinical data scientists attending this event will discuss topics around ... display data collected in clinical studies and beyond. , ...
(Date:9/23/2014)... COLUMBIA, Mo. Infants, vocalizations throughout the first ... crying and cooing to forming syllables and first ... the amount of vocalizations may differ between hearing ... shows that infant vocalizations are primarily motivated by ... infants with profound hearing loss who received cochlear ...
(Date:9/23/2014)... of published studies found that FDG-PET technology is ... disease in regions where infections like histoplasmosis or ... suspicious for cancer could lead to unnecessary tests ... and mortality. , Histoplasmosis and other fungal ... concentrated in bird droppings and are found in ...
(Date:9/23/2014)... World of Home Fitness is committed ... recently, the gym has been raising money to support ... the year, World of Home Fitness has participated in ... Over the summer, World of Home Fitness raised more ... Fitness program, participants helped feed seniors "one rep at ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
Breaking Medicine News(10 mins):Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2
... for, immunization against diphtheria, tetanus, pertussis, polio and Haemophilus ... ... LYON, France, June 23 Sanofi,Pasteur, the vaccines division of ... Administration (FDA) has licensed Pentacel(R),Diphtheria and Tetanus Toxoids and Acellular ...
... of persistent, recent-onset symptoms linked to ovarian cancer ... quickly and abdominal bloating when combined with the ... ovarian cancer by 20 percent, according to new findings ... online today in CANCER . , Research has ...
... Delivery Unit at The Children,s,Hospital of Philadelphia, the ... birth defects, PHILADELPHIA, June 22 Hundreds ... Hospital of Philadelphia for,the 12th Annual Fetal Surgery ... been followed by the Center for Fetal Diagnosis ...
... are struggling with the health fallout caused by a lack ... Most women don,t need a survey to tell them a ... too sluggish to make it through the day with vigor. ... moms, empty-nesters or grandmothers, many -- if not most -- ...
... best in those under 80, could ease expected worldwide shortfall ... blood substitute product called HBOC-201 proved safe and effective in ... reports. , In all, 688 patients, ages 18 and ... unit of blood (about one pint) or an equivalent one ...
... India, June 20 The United States,has provided ... the Children to assist people affected by the ... Shortages have emerged in recent months because the ... rapidly growing rat infestations in,crop-growing areas. With funds ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Symptom screening plus a simple blood test improves early detection of ovarian cancer 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 3Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Blood Substitute Found Safe in Large Phase III Trial 2
The Shandon Cryotome Manual Cryostat features unique formalin fumigation, ergonomic design and automatic defrost. The microtome is located outside the cryochamber for easy cleaning....
... Specimen Processing System is used for tissue ... routine special stains where heat would accelerate ... during immunohistochemistry staining. , Product Detail ... to meet the growing workload demands. This ...
... is a service that directly connects ... the customers laboratory to the Thermo ... U.S.A., and Runcorn, U.K.* By using ... customer site, high-value support services are ...
... The Shandon Excelsior Tissue Processor ... processor using traditional reagents today. ... and outstanding features to provide ... use, increased productivity, reagent cost ...
Medicine Products: